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Monolithic Columns for 
Purification and 
In-process Control of Viruses 
and Virus-like Particles
Lidija Urbas, Miloš Barut
Faro, May 24th 2012
Outline
• Conventional particle based chromatography
• Monolith based chromatography
• Downstream processing of Ad3 VLPs – Case study
• Convective interaction media (CIM) monoliths for in-process 
control – CIMac monolithic analytical columns as a tool for 
HPLC based analytical methods
BIA Separations
• BIA Separations was founded in September 1998.
• Headquartes in Austria, R&D and Production in Slovenia. 
• BIA Separations USA established in September 2007 - sales 
and tech support office.
• BIA Separations China established in January 2011 - sales and 
tech support office.
• Main focus: To develop and sell methacrylate monolithic 
columns & develop methods and processes for large 
biomolecules separation and purification.
Moved to a new 4.200 m2 facility 
in October 2011







• Ion exchange chromatography
• Size exclusion chromatography
• (Pseudo)Affinity chromatography









– Migration of the solutes from an area of high to an area of low
Principle of chromatography: molecule from the mobile phase binds 
to the stationary phase.
concentration
•Convection
– Movement induced by external force
Conventional Liquid Chromatography Media





(contains majority of 
















Binding capacity at high flow rate: f3 > f2 > f1 > f0




























Source 30 S   
IgG (c=0.1 mg/mL)
Courtesy of Prof. A. Jungbauer, IAM, BOKU, Vienna, Austria
elution volume [ml]
































Larger the molecule wider the peak – lower the resolution
Difference Between Diffusive and Convective 
Mass Transport
molecule MW De (cm
2/s)
small molecule 58 Da 1.4 x 10-5
hemoglobin 64 kDa 7 x 10-7
BSA 66 kDa 6.1 x 10-7
urease 482 kDa 3.5 x 10-7
Tomato mosaic virus (ToMV) 40 000 kDa 5 x 10-8
DNA 4.4 kbp 1.9 x 10-8
DNA 3.7 kbp 4,5 x 10-8
The bigger the molecule the lower the rate of diffusion 
Another Challenge – the Size of the
Molecule of Interest
Pores become too small for large solutes!
(Binding mostly on the outer surface)
results in
Very low binding capacity for large solutes  
(behave like nonporous particles)




 Molecule size: surface accessibility
Plasmids 150-250
Rotavirus 130
Poxvirus 200 x 500
T4 phage 220 x 85
Courtesy P. Gagnon www.validated.com
• Monoliths• Membranes
X X X
What Are the Alternatives?
Stacks of thin polymeric layers – supplied 
in single piece but in fact they are
discontinuous unit. 
Monoliths are continuous stationary phases cast as a homogeneous 
column in a single piece.1
CIM Monoliths

























































































What distinguishes monoliths from conventional 
supports?
Structure of the monoliths
• High porosity (over 60 %):
• Flow-through channels (“pores”) 
having large diameter (1.5 µm),
• Uniform channel connectivity in 3D 
(homogeneous structure).
CONSEQUENCE
• Low pressure drop
• High surface accessibility – no dead end pores
• High dynamic binding capacities for large molecules
• Mass transfer predominantly based on CONVECTION
What distinguishes monoliths from conventional 
supports?













































































































































Podgornik et al., Anal. Chem. 72 (2000) 5693
Avaliable CIM Monolithic Columns
0.1 0.34 1 8008 80 80 8000 ml
CIMmultus (multi-use disposable columns)












• Drug Master Files (DMF) for CIM® DEAE, QA and SO3 columns in 
place, HIC in preparation.
• First drug purified using CIM® monoliths passed CPIII trial (pDNA 
for gene therapy).
• More than 25 projects in CPI – CPIII trials (various Influenza, 
various Adenovirus, bacteriophages, various IgMs, Inter-alpha-
CIM® Monoliths for Production of Complex 
Biomolecules
inhibitors).
• More than 200 projects in pre-clinical trials (Influenza A and B 
virus (eggs, Vero and MDCK cells), Rabies virus, Rotavirus, AAV, 
various Adenovirus subtypes, Hepatitis A, Mulv, MVM, Feline 
calicivirus, Japanese encephalitis, Crimean-Congo hemorrhagic 
fever, Hantaan virus, VLP (Hepatitis B, HPV, Influenza, 
Adenovirus), bacteriophages (Lambda, T4, VDX10, Pseudomonas 
phage), Tomato and Pepino Mosaic virus, pDNA, IgM, various 
proteins). 
Downstream Processing of 
Virus-like Particles (VLPs)
Case study
Purification of adenovirus type 3 
dodecahedric VLPs for biomedical 
applications
Work done with the Institute of Biochemistry and Biophysics, 
Polish Academy of Science (Ewa Szolajska and Jadwiga 
Chroboczek).





MW (Ad3 VLPs): 3.6 MDa
MW (base): 63 kDa
Production of Ad3 VLPs
Expression in baculovirus/insect cells system
Cell lysis
Ultracentrifugation in a sucrose density gradient




• Evaluation of CIM monoliths – Chromatographic step
• Direct purification of crude lysate using CIM monoliths
A delivery vector for bleomycin (BLM)
Zochowska et al, Plos One, 2009
Method Development
• HPLC system – detection at 280 nm
• CIMac analytical column (5 x 5.2 mm ID, V = 0.1 mL)
• Ad3 VLPs samples:
– UC sample (sample that was prepurified with 
ultracentrifugation)
– Cell lysate sample
• Methods:
– Ad3 VLPs content - SDS PAGE
– Protein content - BCA, Bradford assay
– DNA content - PicoGreen Analysis, agarose electrophoresis
– Vector internalisation - Confocal Microscopy
Screening of Stationary and Mobile Phases
• Initial screenings performed using the UC (purified) sample,
• Various cation- and anion-exchange monolithic columns,

















































Conditions: buffer A: 20 mM Tris, pH 7.5 + 2 mM EDTA + 5% glycerol, buffer B: buffer A + 1 M NaCl, pH 

























































































Conditions: buffer A: 20 mM Tris, pH 7.5 + 2 mM EDTA + 5% glycerol, buffer B: buffer A + 1 M NaCl, pH 



















































SDS PAGE; M: protein 
marker, L: loading sample, 








































TEM analysis of E3.
Dynamic Binding Capacity
The dynamic binding capacity of Ad3 VLPs is 1.38 × 1016 Ad3 VLPs/mL.










































Ad3 VLPs DNA Conditions: buffer A: 20 mM Tris, 
pH 7.5 + 2 mM EDTA + 5% 
glycerol, buffer B: buffer A+ 1M 
NaCl, pH 7.5; V: 60 µl 3×R cell 
lysate ; detection at 280 nm.
SDS PAGE. M: protein marker, 
FT1-E8: collected fractions.
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t [min]
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SDS PAGE. M: protein marker, 
FT1-E3: collected fractions.
TEM analysis of E2.
Conditions: buffer A: 20 mM Tris, pH 7.5 + 2 mM EDTA + 5% glycerol, buffer B: 
buffer A+ 1M NaCl, pH 7.5; V: 500 µl 5×R cell lysate ; detection at 280 nm.
• less than 1% DNA,
• purification protocol: 1 day.
Vector Internalisation
Incubation of HeLa cells with Ad3 VLPs:
– control: cell nuclei (blue),
– Ad3 VLP Q: cell lysate purified with ultracentrifugation and the agarose matrix.
– Ad3 VLP QA : cell lysate purified on the CIMac QA column (E2 fraction),
Monitoring of Ad3 VLPs with confocal microscopy. Ad3 VLPs stained with green and cell nuclei counterstained 
in blue with DAPI.  Confocal microscopy images show Ad3 VLP in the cytoplasm of HeLa cells after 90 minutes 
of incubation with both samples.
Ad3 VLPs retain their cell penetration capacity.
L. Urbas et al.,J.of Chromatography A, 2011
CIMac Analytical Columns 
for In-process Control
Monolithic Analytical Columns for In-process 
Control (PAT)
10 ml/min = 2800 cm/h = 100 CV/min 











































































































































































Conditions: buffer A: 20 mM Tris, pH 7.5 + 2 mM EDTA + 5% glycerol, buffer B: buffer A+ 1M NaCl, 
pH 7.5; V: 200 µl of 5×disolved sample, method: gradient from 0-100% buffer in 8 min; detection 
at 280 nm.
L. Urbas et al.,J.of Chromatography A, 2011
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PAT of Ad5 Production Using Monolithic HPLC
Eden Biodesign Platform Ad5 Process
•Enzymatic degradation
•Critical to prevent column fouling
•Remove small proteins 
•Decrease process volume
C. Sims et al., MSS 2010, Portoroz, Slovenia, 2010
•Bind and elute
•Virus concentration
•HCP, DNA and endotoxin removal
•More cost and time efficient
•Scalable





Monolithic HPLC used for Ad5 Production Process 

















AEX load SEC eluate
Monolithic HPLC used for the Ad5 
Production Process PAT  
AEX eluate Final Formulation
Whitfield RJ et al., J Chromatography A. 2009
Conclusions
• Novel chromatography supports - monoliths - because of 
their advantages offer a good alternative to 
ultracentrifugation and conventional chromatographic 
support in the field of large molecules.
• Ad3 VLPs were efficiently purified using monoliths:
– Ad3 VLPs were separated from DNA,
– Less than 1% of DNA in the purified fraction,
– Ultracentrifugation could be omitted,
– The morphology of the particles was unaltered,
– Process time was shortened from 5 days to 1 day,
– Ad3 VLPs retained their cell penetration capacity.
• Monolithic analytical columns enable fast and reliable 











Thank you for your attention!
Slovenija
Slovenija
